Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors
MADISON, Wis., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announces the Japanese Patent Office has granted it a patent covering both composition of matter and method of use for CLR 131
View HTML
Toggle Summary Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering
MADISON, Wis., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ("Cellectar" or the "Company"), an oncology-focused biotechnology company, today announces the closing of its registered direct offering, priced at-the-market, of 1,954,388 shares of its common stock and
View HTML
Toggle Summary Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market
MADISON, Wis., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) ("Cellectar" or the "Company"), an oncology-focused biotechnology company, today announced that it entered into securities purchase agreements with certain institutional investors in connection with a
View HTML
Toggle Summary Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates
MADISON, Wis. and CASTRES, France, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), together with leading French pharmaceutical company Pierre Fabre, today announce the extension of their ongoing
View HTML
Toggle Summary Cellectar Biosciences to Present at The MicroCap Conference
MADISON, Wis., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the "company"), today announced that president and CEO Jim Caruso will present and meet with investors at The MicroCap Conference on Thursday, October 5 th at
View HTML
Toggle Summary Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131
MADISON, Wis., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces that a patient treated with the company's lead PDC™ compound, CLR 131 in the fourth cohort of its Phase I dose
View HTML
Toggle Summary Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates
MADISON, Wis., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), and Onconova Therapeutics (Nasdaq:ONTX) today announced that they have entered into a strategic collaboration to develop new
View HTML
Toggle Summary Cellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference
MADISON, Wis., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the "company"), today announced that president and CEO Jim Caruso will present and meet with investors at the Ladenburg Thalmann 2017 Healthcare Conference
View HTML
Toggle Summary Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer
MADISON, Wis., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the "company"), announced that effective today Jarrod Longcor, the company's senior vice president of corporate development and operations, has been promoted to
View HTML
Toggle Summary Cellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference
MADISON, Wis., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the "company"), today announced that it will present and meet with investors at the 19 th Annual Rodman and Renshaw Global Investment Conference on Tuesday,
View HTML